



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 9/00, 9/12, 47/38, 47/36, 31/765</b>		A1	(11) International Publication Number: <b>WO 98/10744</b>  (43) International Publication Date: <b>19 March 1998 (19.03.98)</b>
(21) International Application Number: <b>PCT/GB97/02455</b>  (22) International Filing Date: <b>10 September 1997 (10.09.97)</b>		(81) Designated States: AU, CA, CH, JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data:  9619091.3 12 September 1996 (12.09.96) GB 9705844.0 21 March 1997 (21.03.97) GB		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71)(72) Applicants and Inventors: BARTON, Simon, Everard [GB/GB]; 52 Keswick Avenue, Merton Park, London SW19 3JE (GB). SMITH, James, Richard [GB/GB]; Flat 2, 193 Sutherland Avenue, Little Venice, London W9 1ET (GB). KELL, Philip, David [GB/GB]; 44 Grosvenor Road, Muswell Hill, London N10 2DS (GB).			
(74) Agent: WOODCRAFT, David, Charles; Brookes & Martin, High Holborn House, 52/54 High Holborn, London WC1V 6SE (GB).			
(54) Title: COMPOSITION COMPRISING AN ANTIVIRAL OR ANTIBACTERIAL AGENT FOR PREVENTING TRANSMISSION OF DISEASES			
(57) Abstract			
<p>Prophylactic compositions are disclosed which are effective in providing protection against the transmission of HIV infection during sexual activities. The compositions are based on synthetic saliva and incorporate a virucidal agent and preferably also an anti-bacterial agent.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	I.C	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**COMPOSITION COMPRISING AN ANTIVIRAL OR ANTIBACTERIAL AGENT FOR PREVENTING TRANSMISSION OF DISEASES**

This invention relates to prophylactic compositions. Since the onset of the AIDS epidemic, there has been increasing emphasis on the promotion of so-called "safe sex". The surrounding educational efforts have largely concentrated on the promotion of the male condom which provides reasonable protection against transmission of HIV infection during conventional sexual activities.

Until recently, it was thought that oral sexual contacts did not produce any significant risk of transmission of the HIV virus, although there are already proven risks of transmission by oral contact in the case of other sexually-transmitted diseases such as gonorrhoea, herpes, warts, streptococcal infections and hepatitis B. Recent studies on monkeys, however, have shown that the related SIV virus can be transmitted orally.

It is, therefore, an object of the present invention to provide a prophylactic composition useful in reducing the transmission of sexually-transmitted diseases (STD) and transmission of diseases by orogenital sexual contact.

It is also an object of the present invention to provide a prophylactic composition which is useful also in reducing the risk of sexual transmission of pathogens during genital to genital and genital to manual sexual contact.

According to the present invention, therefore, there is provided a prophylactic composition effective in reducing the transmission of diseases by oral/genital, genital/genital or genital/manual contact, which comprises an active ingredient comprising an effective amount of an anti-viral or anti-bacterial agent in a liquid vehicle simulating natural saliva. In contrast with a normal mouth rinse, the

compositions of the invention can be formulated to have an effect extending over the duration of sexual contact. Thus, protection is provided for the necessary period required.

The compositions can be formulated so as to be effective against viral and bacterial STDs and other viruses and bacteria which might be transmitted in the course of sex, in particular oral sex, e.g. hepatitis B and human papilloma virus. A range of anti-viral agents exist and include, e.g. polyethylene glycol alkylphenylethers such as the nonyl and octyl homologues marketed under the trade names "Nonoxynol" and "Octoxynol" and di-isobutyl phenoxy polyethoxyethanol. These agents are non-ionic surfactants and are believed to owe their virucidal activity to their ability to disrupt viral membrane integrity. 'Nonoxynol' and 'Octoxynol' are manufactured respectively by Cilag Limited and ICI. In order to be effective in combating bacterial and viral agents within the mouth, the anti-bacterial or anti-viral agents should generally be present in an amount of from about 0.05 to 0.2 percent by weight, typically about 0.1 percent. For protection against HIV transmission, the anti-viral agent should be present in an amount of at least about 0.25%.

Anti-bacterial agents should preferably be included in the compositions of the invention along with the anti-viral agents. When used together with the anti-viral agent, the anti-bacterial agent should preferably be present in a concentration of at least 0.05%, preferably at 0.1%. Typical anti-bacterial agents include quaternary ammonium salts, such as benzalkonium chloride and cetrimide, imidazoles, such as metronidazole, clotrimazole, and miconazole, and antiseptics such as chlorhexidine acetate and gluconate.

The liquid vehicle in which the active agent is dissolved or dispersed comprises a viscous, slightly sticky material, having a viscosity and physical properties very similar to that of natural saliva. Such materials are currently available on the market as synthetic salivas and one commercial composition is available under the trade name "Saliva Orthana", manufactured by A. S. Orthana Kemisk Fabrik, Denmark. The composition is based on natural mucin extracted from pigs stomachs.

Other base materials suitable for the manufacture of synthetic salivas include cellulose derivatives, such as carboxymethyl cellulose. Commercially available synthetic salivas based on cellulose derivatives include 'Glandsane' and 'Salivace'. Synthetic salivas are currently prescribed for patients having eating, swallowing and speech difficulties, caused by a reduction in the production of natural salivas e.g. by cancer of the head and neck region. The paper by Vissink et al in International Journal of Oral Surgery, 1983, 12, pages 232 to 238, describes a typical saliva preparation and their use in the treatment of patients having depressed saliva production.

In accordance with the invention the anti-bacterial and/or anti-viral agent is dispersed in an effective amount in the synthetic saliva. The use of a vehicle simulating natural saliva as a carrier for the anti-bacterial and/or anti-viral agent is thought to aid greater adhesion of the active ingredient to the mucosa, whether in the mouth, vagina or anus. The resulting composition may be packaged in single dose sachets containing about 2.5 ml of the liquid prophylactic composition.

For example, just before sexual contact is anticipated, the passive partner can break the sachet and spread the synthetic saliva around the mouth. Other methods of dispensing the material include a water-soluble or chewable capsule or tablet. In the case of a tabletted composition, the ingredients will include hydrophilic materials or materials causing a rapid break-up of the tablet and the formation of a coating of synthetic saliva on the buccal and lingual surfaces. However, preferably, the compositions of the invention are packaged in an aerosol can or oral spray container. In the latter case, the spray container may be fitted with a metering pump so that the user sprays a measured amount of say 2-5 mls into the mouth.

For use of the prophylactic composition of the present invention in reducing transmission of diseases transmitted by genital/genital or genital/manual contact, alternative delivery/packaging systems may be preferred, in particular where the composition is to be applied, initially, to non-mucosal surfaces such as the hands.

One example of a typical formulation for the compositions of the invention is given below:-

**Manufacturing Formula**

The manufacturing formula for the preparation of 1 litre is:

Mucin (hog stomach) solution 4% in water	875 g
Xylitol	20 g
Methyl-4-hydroxybenzoate ) (Preservatives)	1 g
Benzalkonium chloride solution, 50%)	0.04 g
Ethylenediaminetetraacetic acid	
disodium salt x 2 H <sub>2</sub> O	(Buffer)
Hydrogen peroxide solution, 35%	(Sterilising agent) max. 0.86 g

Peppermint oil )	(Flavouring)	0.05 g
Spearmint oil )		0.05 g
Nonoxynol-9 (Cilag Ltd).		3 g
Purified water M		to 1 litre

In an alternative formulation, the mucin solution can be replaced by carboxymethyl cellulose in an amount of about 10 g of the solid material per litre of the made up composition.

**CLAIMS:-**

1. A prophylactic composition effective in reducing the transmission of diseases transmitted by oral/genital, genital/genital or genital/manual contact which comprises an active ingredient comprising an effective amount of an anti-bacterial or anti-viral agent in a vehicle simulating natural saliva.
2. A composition as claimed in claim 1 wherein the anti-viral agent is a poly(ethylene)glycol-alkylphenylether.
3. A composition as claimed in claim 2 wherein the anti-viral agent is nonylphenoxy-polyethoxy ethanol or octylphenoxy-polyethoxy ethanol.
4. A composition as claimed in any one of the preceding claims which contains both an anti-viral and an anti-bacterial agent.
5. A composition as claimed in any one of the preceding claims wherein the anti-viral agent is present in a concentration of at least 0.25% by weight.
6. A composition as claimed in any one of the preceding claims wherein the liquid vehicle comprises an aqueous solution or dispersion of a cellulose derivative or natural mucin.
7. A composition as claimed in claim 6 wherein the cellulose derivative is carboxymethyl cellulose.
8. A composition as claimed in any one of the preceding claims which is packaged as an aerosol or as an oral spray.
9. The use of a composition comprising an effective amount of an anti-bacterial anti-viral agent in a vehicle simulating natural saliva in the reduction of sexual transmission of diseases.

10. The use of an anti-bacterial or anti-viral agent and a vehicle simulating natural saliva in the preparation of a medicament for reducing the sexual transmission of diseases.
11. The use as claimed in claim 9 or claim 10 wherein the sexual transmission occurs through oral/genital contact.
12. The use as claimed in claim 9 or claim 10 wherein the sexual transmission occurs through genital/genital or genital/anal contact.
13. The use as claimed in any one of claims 9 to 12 wherein the anti-viral agent is a poly(ethylene)glycol-alkylphenylether; preferably nonylheoxy-polyepoxy ethanol or octylphenoxy-polyethoxy ethanol.
14. The use as claimed in any one of claims 9 to 13 which contains both an anti-viral and an anti-bacterial agent.
15. The use as claimed in any one of claims 9 to 14 wherein the anti-viral agent is present in a concentration of at least 0.25% by weight.
16. The use as claimed in any one of claims 9 to 15 wherein the liquid vehicle comprises an aqueous solution or dispersion of a cellulose derivative or natural mucin.
17. The use as claimed in claim 16 wherein the cellulose derivative is caboxymethyl cellulose.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB 97/02455

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 A61K9/00 A61K9/12 A61K47/38 A61K47/36 A61K31/765

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 92 16201 A (MICHAELS E B RES ASS) 1 October 1992 see page 3, line 19 - line 29 see page 18, line 33 - page 19, line 19 see claims 1-19 ---	1-17
X	WO 95 08981 A (UNION CARBIDE CHEM PLASTIC ;BRODE GEORGE LEWIS (US); KREEGER RUSSE) 6 April 1995 see page 26, paragraph 2-4 ---	1-17
X	EP 0 636 374 A (JOHNSON & JOHNSON CONSUMER) 1 February 1995 see examples 1-3,5-7 see claims 1-10 ---	1-17 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*Z\* document member of the same patent family

1

Date of the actual completion of the international search

Date of mailing of the international search report

27 January 1998

06.02.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Seegert, K

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB 97/02455

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 351 301 A (SSPL SA SAFE SEX PROD LICENS) 17 January 1990 see column 5 - column 6 ---	1-17
X	CA 2 132 688 A (LIVINGSTON GEORGE M ;THORNBURGH DAVID B (CA); LONGMORE JEFFREY (US) 23 March 1996 see claims 1-5 -----	1-17

1

# INTERNATIONAL SEARCH REPORT

## Information on patent family members

International application No  
PCT/GB 97/02455

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9216201 A	01-10-92	US 5314917 A		24-05-94
		AU 661968 B		17-08-95
		AU 8222791 A		21-10-92
		CA 2106683 A		23-09-92
		EP 0576425 A		05-01-94
		EP 0733361 A		25-09-96
		JP 6505700 T		30-06-94
		OA 9911 A		15-09-94
		US 5389676 A		14-02-95
<hr/>				
WO 9508981 A	06-04-95	US 5407919 A		18-04-95
		AU 8011594 A		18-04-95
		CA 2173101 A		06-04-95
		EP 0721326 A		17-07-96
		JP 9503763 T		15-04-97
		US 5595980 A		21-01-97
		ZA 9407572 A		28-09-95
<hr/>				
EP 0636374 A	01-02-95	AU 6873694 A		09-02-95
		BR 9402963 A		11-04-95
		CA 2128954 A		29-01-95
		JP 7145063 A		06-06-95
		US 5512289 A		30-04-96
		ZA 9405563 A		29-01-96
<hr/>				
EP 0351301 A	17-01-90	AP 108 A		23-02-91
		AU 625716 B		16-07-92
		AU 3802689 A		11-01-90
		CN 1041879 A		09-05-90
		CZ 8904238 A		13-12-95
		DE 68910892 D		05-01-94
		DE 68910892 T		05-05-94
		DK 340289 A		12-01-90
		ES 2062065 T		16-12-94
		HK 131095 A		24-08-95
		HR 921074 A		30-06-95
		IE 63115 B		22-03-95
		IL 90910 A		29-12-94
		JP 2051502 C		10-05-96
		JP 2167235 A		27-06-90

# INTERNATIONAL SEARCH REPORT

## Information on patent family members

International Application No  
PCT/GB 97/02455

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0351301 A		JP 7074164 B LT 1660 A, B LV 10573 B MX 170801 B NO 178843 B OA 9123 A PL 161848 B PT 91108 B SK 423889 A RU 2065742 C US 5439685 A	09-08-95 25-07-95 20-08-95 14-09-93 11-03-96 31-10-91 31-08-93 31-01-95 05-11-97 27-08-96 08-08-95
CA 2132688 A	23-03-96	NONE	